Skip to content
Clinical Trials – home
Not yet recruiting

A Phase I/II Study of IPN60330 in Adults with Advanced Solid Tumors to Assess Safety, Tolerability, and Optimal Dosing

InvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on adults who have either Metastatic Solid Tumor or Locally Advanced Solid Tumor. A solid tumor is a lump of abnormal cells that can grow and sometimes spread to other parts of the body; “metastatic” means the cancer has already spread, while “locally advanced” means it has grown large or invaded nearby tissues but has not yet spread far. The investigational medication being tested is identified by the code name IPN60330, which is given through an IV infusion, a method where the drug is delivered directly into a vein.

The purpose of the study is to learn about the safety and effects of this new medication. Participants will start with a low dose of the drug, and the amount may be gradually increased to find a level that is both safe and potentially effective. Throughout the trial, researchers will watch for any side effects and will also look for signs that the tumor is responding, such as shrinking in size. The early part of the study (phase Ia) is focused on safety, while the later part (phase Ib) aims to determine the best dosing schedule for the selected tumor type.

The research process

The trial runs in 12 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Start of Study Participation

    You are enrolled in a study that evaluates the safety and effects of IPN60330 in adults with advanced solid tumors.

    The study proceeds in two parts: Phase Ia focuses on safety and finding the highest dose that can be tolerated, while Phase Ib aims to identify the best dosing schedule for a selected tumor type.

  2. Step 2

    Baseline Assessments

    Before receiving any medication, you will undergo medical history review, physical examinations, blood tests, and imaging scans to document the status of your disease.

    These assessments create a reference point for later comparisons.

  3. Step 3

    First Infusion of IPN60330

    You will receive IPN60330 as an intravenous (IV) infusion. The exact amount and schedule are defined by the study protocol and may be adjusted during the trial.

    The infusion is administered in a clinical setting under medical supervision.

  4. Step 4

    Monitoring for Dose‑Limiting Toxicities

    After the first dose, you will be closely observed for any side effects that are severe enough to limit further dose increases. These are called dose‑limiting toxicities (DLTs).

    Monitoring includes regular vital‑sign checks, laboratory tests, and symptom questionnaires during the first treatment cycle.

  5. Step 5

    Dose Escalation (Phase Ia)

    If no DLTs are observed, the dose may be increased in subsequent cycles according to a predefined escalation plan.

    Each new dose level is followed by the same safety monitoring to ensure tolerability.

  6. Step 6

    Determination of Maximum Tolerated or Administered Dose

    The study team will identify the highest dose that can be given safely, known as the maximum tolerated dose (MTD) or maximum administered dose (MAD).

    You will continue receiving the drug at this dose for the remainder of the Phase Ia portion.

  7. Step 7

    Transition to Phase Ib (Optimal Dosing)

    If your tumor type is selected for Phase Ib, the study will move to determine the optimal dosing schedule for IPN60330 based on the safety data from Phase Ia.

    You will receive regular infusions at the dose identified as optimal.

  8. Step 8

    Ongoing Safety Assessments

    Throughout the trial, any new or worsening side effect after the first dose is recorded as a treatment‑emergent adverse event (TEAE).

    Serious side effects that occur after the first dose are recorded as treatment‑emergent serious adverse events (TESAEs).

    These events are evaluated at each visit to ensure your safety.

  9. Step 9

    Disease Evaluation

    Periodically, imaging scans are performed to assess how the tumor responds to the treatment.

    The study measures the objective response rate (ORR), which is the percentage of participants whose tumors shrink enough to be classified as a complete or partial response.

  10. Step 10

    Continuation of Treatment

    You will continue receiving infusions of IPN60330 until disease progression, unacceptable toxicity, or the end of the study period, whichever occurs first.

    Each treatment cycle follows the schedule defined by the protocol.

  11. Step 11

    End‑of‑Treatment Visit

    When treatment stops, you will have a final set of assessments, including physical examination, laboratory tests, and imaging, to document the overall outcome of the study.

  12. Step 12

    Follow‑Up Period

    After the end of treatment, you will attend scheduled follow‑up visits to monitor your health and to detect any late‑appearing effects of the drug.

    These visits may include simple safety checks and questionnaires.

Who can join the trial?

9 criteria

  • Adults aged 18 or older – you must be at least 18 years of age.
  • You must have a solid tumor that is either locally advanced (large in one area) or metastatic (spread to other parts of the body). The diagnosis must be confirmed by laboratory examination of your tissue (called histology or cytology). The tumor must have come back after previous treatment or not responded to the usual treatments, or there may be no standard treatment available.
  • You need to have disease that can be measured with imaging tests according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. This means at least one tumor that can be seen and measured on scans and has not been treated before.
  • Your overall health must be good enough to have an ECOG performance status of 0‑1. This scale rates how well you can carry out daily activities, where 0 means fully active and 1 means able to do light work.
  • You should be expected to live more than 3 months from the time of enrollment.
  • Your major organs (such as liver, kidneys, blood‑forming organs) must be functioning well enough, as shown by standard laboratory tests.
  • You must be willing and able to sign a written informed consent form, which explains the study and your rights.
  • You must agree to follow all study rules, including using appropriate contraception (birth control) if required.
  • You need to provide a sample of your tumor tissue at the screening visit for testing of specific markers called biomarkers, including a protein named GPC3. Additional tissue samples may be taken during the study for certain participants.

Who cannot join the trial?

15 criteria

  • Having another cancer that needs treatment within the last 2 years (except for cancers that were fully cured and are not currently active).
  • Using medicines that suppress the whole‑body immune system, such as taking 10 mg or more of prednisone (or an equivalent drug). Regular low‑dose steroids for hormone replacement, allergy prevention, or inhaled/topical use are allowed.
  • Getting a live or weakened (attenuated) vaccine within 4 weeks before the study drug is started.
  • Being pregnant or breastfeeding.
  • Having a known allergy (hypersensitivity) to the study drug or any of its ingredients.
  • Participating in another experimental drug study and not completing the required “washout” time (the period needed for the previous study drug to leave the body).
  • Having any health problem that the doctor thinks could make it unsafe or difficult to stay in the study.
  • Still having side effects from previous cancer treatments that are rated as Grade 2 or higher on the NCI CTCAE v6.0 scale (a system doctors use to grade side effects), except for hair loss (alopecia) or stable, mild side effects that the doctor judges to be acceptable.
  • Having had a serious reaction called Cytokine Release Syndrome or a nerve problem called Immune Effector Cell‑Associated Neurotoxicity Syndrome that was considered unacceptable.
  • Having previously taken a targeted cancer drug that works in the same way as the study drug.
  • Receiving recent cancer treatment without the required washout period (the time needed for the previous treatment to clear from the body).
  • Having active or uncontrolled serious medical problems, such as heart (cardiovascular), lung (pulmonary), nerve (neurological), or digestive (gastrointestinal) disorders.
  • Having an active infection that is not under control, including bacterial infections treated with oral or IV antibiotics within the past 7 days, or significant viral infections. Infections like HIV or Hepatitis B are allowed only if the virus is well‑controlled with medication.
  • Having an active autoimmune disease (where the immune system attacks the body) that required systemic treatment in the past 2 years.
  • Having active cancer spread to the brain or the lining of the brain and spinal cord (leptomeningeal metastases). Small, symptom‑free brain spots or brain disease that has been treated and is stable are allowed.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

IPN60330 is an experimental medicine being given by intravenous infusion. In this first‑in‑human study, the drug is being tested in adults who have advanced solid tumors that cannot be removed by surgery. Researchers are looking at how safe the medicine is, how well patients can tolerate it, and how the body processes it. They are also measuring whether the drug can trigger an immune response and if it shows any signs of shrinking or stopping the growth of tumors. The study starts with low doses and gradually increases them to find the best and safest amount to give.

What is already known about the treatment

IPN60330 - IPN60330 is given as a sterile solution that is infused into a vein through an IV line. It is currently an investigational drug being studied in a first‑in‑human phase I/II trial and has not yet received any regulatory approval. The drug is being tested for treatment of locally advanced or metastatic solid tumors. It works by binding to a protein on cancer cells and blocking the signals that tell the cells to grow and survive, placing it in the class of experimental anticancer agents.

Investigated diseases

  • Metastatic solid tumor

    A solid tumor that has spread from its original location to distant organs or tissues. Cancer cells travel through the bloodstream or lymphatic system and form new growths elsewhere in the body. The disease often progresses by establishing multiple secondary lesions that can grow independently. As these new sites enlarge, they may cause symptoms related to the affected organ. The spread can continue, making the overall disease burden increase over time.

  • Locally advanced solid tumor

    A solid tumor that has grown beyond its site of origin and involves nearby structures or lymph nodes but has not yet spread to distant organs. The tumor may infiltrate surrounding tissues, making surgical removal more difficult. Over time, the lesion can enlarge and compress or invade adjacent organs, leading to functional impairment. Local spread can also increase the risk of eventual distant dissemination. The disease typically follows a pattern of gradual expansion within the regional area.

Trial detailsLast updated 21 Nov 2026
Age18+ yearsPhasePhase I/IITrial ID2026-527238-30-00Protocol codeCLIN-60330-450Estimated enrolment69 patientsSponsorIpsen Pharma

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.